Maze Therapeutics, Inc.
Maze Therapeutics, Inc. (MAZE) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · MAZE · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
46
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Maze Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
MAZE insider buying and selling by quarter
MAZE insider selling · MAZE insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · MAZE ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
MAZE executive sell shares · MAZE board member insider trading · MAZE insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Jun 1, 2026 | Coloma Jason V CEO · Director | Sale | 6,090 | $160K | Form 4 |
| Jun 1, 2026 | Coloma Jason V CEO · Director | Sale | 553 | $15K | Form 4 |
| Jun 1, 2026 | Bernstein Harold President, R&D & CMO | Option | 14,853 | $155K | Form 4 |
| Jun 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 13,253 | $339K | Form 4 |
| Jun 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 1,600 | $42K | Form 4 |
| May 29, 2026 | Dandekar Atul CSBO | Option | 7,500 | $78K | Form 4 |
| May 29, 2026 | Dandekar Atul CSBO | Sale | 7,500 | $198K | Form 4 |
| May 22, 2026 | Coloma Jason V CEO · Director | Sale | 4,504 | $117K | Form 4 |
| May 26, 2026 | Coloma Jason V CEO · Director | Sale | 25,582 | $666K | Form 4 |
| May 22, 2026 | Coloma Jason V CEO · Director | Sale | 2,478 | $64K | Form 4 |
| May 15, 2026 | Coloma Jason V CEO · Director | Sale | 1,822 | $47K | Form 4 |
| May 15, 2026 | Coloma Jason V CEO · Director | Sale | 116 | $3K | Form 4 |
| May 14, 2026 | Bernstein Harold President, R&D & CMO | Option | 15,000 | $156K | Form 4 |
| May 14, 2026 | Bernstein Harold President, R&D & CMO | Sale | 15,000 | $393K | Form 4 |
| May 4, 2026 | Dandekar Atul CSBO | Option | 5,985 | $62K | Form 4 |
| May 4, 2026 | Dandekar Atul CSBO | Option | 8,320 | $87K | Form 4 |
| May 4, 2026 | HOMCY CHARLES J Director | Gift | 7,422 | — | Form 4 |
| Apr 29, 2026 | Dandekar Atul CSBO | Option | 7,500 | $78K | Form 4 |
| Apr 29, 2026 | Dandekar Atul CSBO | Sale | 7,500 | $190K | Form 4 |
| Apr 1, 2026 | Bernstein Harold President, R&D & CMO | Option | 15,000 | $156K | Form 4 |
| Apr 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 11,352 | $332K | Form 4 |
| Apr 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 3,348 | $101K | Form 4 |
| Apr 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 300 | $9K | Form 4 |
| Apr 1, 2026 | Bachrodt Amy SVP, Finance | Option | 2,500 | $26K | Form 4 |
| Apr 1, 2026 | Bachrodt Amy SVP, Finance | Sale | 2,200 | $65K | Form 4 |
Bernstein Harold
President, R&D & CMO
Date
Jun 1
Shares
14,853
Price
$10.42
Value
$155K
Bernstein Harold
President, R&D & CMO
Date
Jun 1
Shares
13,253
Price
$25.57
Value
$339K
Bernstein Harold
President, R&D & CMO
Date
Jun 1
Shares
1,600
Price
$26.36
Value
$42K
Bernstein Harold
President, R&D & CMO
Date
May 14
Shares
15,000
Price
$10.42
Value
$156K
Bernstein Harold
President, R&D & CMO
Date
May 14
Shares
15,000
Price
$26.22
Value
$393K
Bernstein Harold
President, R&D & CMO
Date
Apr 1
Shares
15,000
Price
$10.42
Value
$156K
Bernstein Harold
President, R&D & CMO
Date
Apr 1
Shares
11,352
Price
$29.24
Value
$332K
Bernstein Harold
President, R&D & CMO
Date
Apr 1
Shares
3,348
Price
$30.06
Value
$101K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About MAZE insider trading
MAZE insider trades
Maze Therapeutics, Inc. (MAZE) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Bernstein Harold (President, R&D & CMO), Bachrodt Amy (SVP, Finance), Dandekar Atul (CSBO). Over the past 12 months, 5 insiders have filed transactions with the SEC. MAZE insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Maze Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
MAZE insider trading · 5 questionsThe insiders of Maze Therapeutics, Inc. (MAZE) include executives and directors such as Bernstein Harold (President, R&D & CMO), Bachrodt Amy (SVP, Finance), Dandekar Atul (CSBO), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026